An individual patient data meta-analysis recently ascertained the accuracy of circulating tumor DNA (ctDNA) for the detection of PIK3CA mutations, raising the possibility of replacing tissue for ctDNA tumor sampling in the future as a preferred strategy for metastatic breast cancer patients with low clinical compliance or inaccessible metastatic sites (Galvano et al., 2022). Here, PIK3CA is linked to breast carcinoma.